BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34747637)

  • 1.
    Liu S; Gao C; Wu Y; Lin W; Li J; Xue T; Wang L; Zheng H; Zhang R
    Pharmacogenomics; 2021 Nov; 22(17):1135-1142. PubMed ID: 34747637
    [No Abstract]   [Full Text] [Related]  

  • 2. Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.
    Fernandez CA; Smith C; Yang W; Mullighan CG; Qu C; Larsen E; Bowman WP; Liu C; Ramsey LB; Chang T; Karol SE; Loh ML; Raetz EA; Winick NJ; Hunger SP; Carroll WL; Jeha S; Pui CH; Evans WE; Devidas M; Relling MV
    Blood; 2015 Jul; 126(1):69-75. PubMed ID: 25987655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-DRB1*07:01-HLA-DQA1*02:01-HLA-DQB1*02:02 haplotype is associated with a high risk of asparaginase hypersensitivity in acute lymphoblastic leukemia.
    Kutszegi N; Yang X; Gézsi A; Schermann G; Erdélyi DJ; Semsei ÁF; Gábor KM; Sági JC; Kovács GT; Falus A; Zhang H; Szalai C
    Haematologica; 2017 Sep; 102(9):1578-1586. PubMed ID: 28596278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies.
    Fernandez CA; Smith C; Yang W; Daté M; Bashford D; Larsen E; Bowman WP; Liu C; Ramsey LB; Chang T; Turner V; Loh ML; Raetz EA; Winick NJ; Hunger SP; Carroll WL; Onengut-Gumuscu S; Chen WM; Concannon P; Rich SS; Scheet P; Jeha S; Pui CH; Evans WE; Devidas M; Relling MV
    Blood; 2014 Aug; 124(8):1266-76. PubMed ID: 24970932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HLA alleles associated with asparaginase hypersensitivity in Chinese children.
    Chua GT; Rosa Duque JS; Cheuk DKL; Leung AWK; Wong WHS; Liu APY; Lee PPW; Ha SY; Chiang AKS; Ho MHK; Chu WK; Chan YS; Luk CW; Ling ASC; Kwan MYW; Yiu OKF; Wong ICK; Lau YL; Li CK; Leung WH; Chan GCF; Ip P; Kwok J
    J Hematol Oncol; 2021 Oct; 14(1):182. PubMed ID: 34717720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008.
    Højfeldt SG; Wolthers BO; Tulstrup M; Abrahamsson J; Gupta R; Harila-Saari A; Heyman M; Henriksen LT; Jónsson ÒG; Lähteenmäki PM; Lund B; Pruunsild K; Vaitkeviciene G; Schmiegelow K; Albertsen BK;
    Br J Haematol; 2019 Feb; 184(3):405-417. PubMed ID: 30450575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Characteristics of Intravenous PEG-Asparaginase Hypersensitivity Reactions in Patients Undergoing Treatment for Acute Lymphoblastic Leukemia [Formula: see text].
    Browne EK; Moore C; Sykes A; Lu Z; Jeha S; Mandrell BN
    J Pediatr Oncol Nurs; 2018; 35(2):103-109. PubMed ID: 29161979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEG-asparaginase allergy in children with acute lymphoblastic leukemia in the NOPHO ALL2008 protocol.
    Henriksen LT; Harila-Saari A; Ruud E; Abrahamsson J; Pruunsild K; Vaitkeviciene G; Jónsson ÓG; Schmiegelow K; Heyman M; Schrøder H; Albertsen BK;
    Pediatr Blood Cancer; 2015 Mar; 62(3):427-33. PubMed ID: 25418987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA alleles associated with asparaginase hypersensitivity in childhood ALL: a report from the DFCI Consortium.
    Gagné V; St-Onge P; Beaulieu P; Laverdière C; Leclerc JM; Tran TH; Sallan SE; Neuberg D; Silverman LB; Sinnett D; Krajinovic M
    Pharmacogenomics; 2020 Jun; 21(8):541-547. PubMed ID: 32372697
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group.
    Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP
    Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of hypersensitivity rates to intravenous and intramuscular PEG-asparaginase in children with acute lymphoblastic leukemia: A meta-analysis and systematic review.
    Hasan H; Shaikh OM; Rassekh SR; Howard AF; Goddard K
    Pediatr Blood Cancer; 2017 Jan; 64(1):81-88. PubMed ID: 27578304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866).
    Kurtzberg J; Asselin B; Bernstein M; Buchanan GR; Pollock BH; Camitta BM
    J Pediatr Hematol Oncol; 2011 Dec; 33(8):610-6. PubMed ID: 22042277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower incidence of clinical allergy with PEG-asparaginase upfront versus the sequential use of native E. coli asparaginase followed by PEG-ASP in pediatric patients with acute lymphoblastic leukemia.
    Mesegué M; Alonso-Saladrigues A; Pérez-Jaume S; Comes-Escoda A; Dapena JL; Faura A; Conde N; Català A; Ruiz-Llobet A; Zapico-Muñiz E; Camós M; Rives S
    Hematol Oncol; 2021 Dec; 39(5):687-696. PubMed ID: 34397119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Leucocyte Antigen alleles associated with asparaginase hypersensitivity in childhood Acute Lymphoblastic Leukemia patients treated with Pegylated asparaginase within Dana Farber Cancer Institute treatment protocols.
    Kondyli M; Tremblay DÉ; Rezgui A; Serfaty SA; Gagné V; Ribère M; Laverdière C; Leclerc JM; Tran TH; Sinnett D; Krajinovic M
    Leuk Res; 2021 Oct; 109():106650. PubMed ID: 34198115
    [No Abstract]   [Full Text] [Related]  

  • 15. Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06.
    Albertsen BK; Harila-Saari A; Jahnukainen K; Lähteenmäki P; Riikonen P; Möttönen M; Lausen B
    Leuk Lymphoma; 2019 Jun; 60(6):1469-1475. PubMed ID: 30632847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
    Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
    J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase.
    Mark C; Gupta S; Punnett A; Upton J; Orkin J; Atkinson A; Clarke L; Heisey A; McGovern C; Alexander S
    Pediatr Blood Cancer; 2021 Nov; 68(11):e29295. PubMed ID: 34398511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New possibilities of treatment with PEG-L-asparaginase in patients with acute lymphoblastic leukemia sensitized to l-asparaginase E.coli and erwinase].
    Sikorska-Fic B; Makowska K; Rokicka-Milewska R
    Wiad Lek; 1998; 51 Suppl 4():233-6. PubMed ID: 10731974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of hypersensitivity reactions to PEG-asparaginase in children after intravenous and intramuscular administration.
    August KJ; Miller WP; Dalton A; Shinnick S
    J Pediatr Hematol Oncol; 2013 Oct; 35(7):e283-6. PubMed ID: 23619117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.